Cover
Cover | Aug. 08, 2022 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | This Current Report on Form 8-K/A (this “Amendment No. 1”) amends the Current Report on Form 8-K filed by Allarity Therapeutics, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on August 12, 2022 (the “Original Form 8-K”), in which the Company disclosed that it had received a written notification from its former independent registered public accounting firm, Marcum LLP (“Former Accountant”) that its client-auditor relationship with the Company had ceased to be effective as of August 5, 2022. This Amendment No. 1 is being filed to (i) update certain information under Item 4.01, and (ii) file as an exhibit under Item 9.01(d) of this Amendment No. 1 the letter regarding the change in certifying accountant received from the Former Accountant. This Amendment No. 1 should be read in conjunction with the Original Form 8-K and does not modify or update any disclosure made in the Original Form 8-K unless otherwise amended in this Amendment No. 1. |
Document Period End Date | Aug. 08, 2022 |
Entity File Number | 001-41160 |
Entity Registrant Name | ALLARITY THERAPEUTICS, INC. |
Entity Central Index Key | 0001860657 |
Entity Tax Identification Number | 87-2147982 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 210 Broadway |
Entity Address, Address Line Two | Suite 201 |
Entity Address, City or Town | Cambridge |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02139 |
City Area Code | 401 |
Local Phone Number | 426-4664 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Trading Symbol | ALLR |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |